Chen H-S, Wu T-E J, Jap T-S, Lu R-A, Wang M-L, Chen R-L, Lin H-D
Division of Endocrinology and Metabolism, Department of Medicine, Taipei Veterans General Hospital, Taiwan.
Diabet Med. 2007 Dec;24(12):1336-44. doi: 10.1111/j.1464-5491.2007.02270.x. Epub 2007 Oct 17.
The purpose of this study was to determine the relationship between subclinical hypothyroidism and prevalence of retinopathy and nephropathy, incident cardiovascular disease, and mortality in Type 2 diabetic patients without taking thyroid medication.
Serum thyrotropin and free thyroxine concentrations were measured in 588 Type 2 diabetic subjects in Taipei Veterans General Hospital, Taiwan. In a cross-sectional study, we examined the prevalence of retinopathy and nephropathy. In a longitudinal study, we examined the risk of cardiovascular disease events, cardiovascular mortality and total mortality in the 4-year follow-up.
In the cross-sectional analysis, subclinical hypothyroidism was associated with a greater prevalence of diabetic nephropathy (odds ratio, 3.15 [95% CI, 1.48-6.69]) and did not show a high prevalence of diabetic retinopathy (odds ratio, 1.15 [95% CI, 0.59-2.26]) compare to euthyroid diabetics. During the 44.0 +/- 7.4 months of follow-up, 51 participants had cardiovascular events. The risk of cardiovascular events was significantly increased in Type 2 diabetics with subclinical hypothyroidism after adjustment for age, sex, A1C, other standard cardiovascular risk factors and medication (hazard ratio, 2.93; 95% CI, 1.15-7.48; P = 0.024), but it became nonsignificant after additional adjustment for urinary albumin-to-creatinine ratio (hazard ratio, 2.06; 95% CI, 0.67-6.36; P = 0.211). The rates of cardiovascular-related and total mortality did not significantly differ by thyroid status.
Type 2 diabetic patients with subclinical hypothyroidism are associated with an increased risk of nephropathy and cardiovascular events, but not with retinopathy. Our data suggest that the higher cardiovascular events in subclinical hypothyroidism with Type 2 diabetes may be mediated with nephropathy.
本研究旨在确定未服用甲状腺药物的2型糖尿病患者亚临床甲状腺功能减退与视网膜病变和肾病患病率、心血管疾病发生率及死亡率之间的关系。
对台湾台北荣民总医院的588名2型糖尿病患者测定血清促甲状腺激素和游离甲状腺素浓度。在一项横断面研究中,我们检查了视网膜病变和肾病的患病率。在一项纵向研究中,我们在4年随访中检查了心血管疾病事件、心血管死亡率和总死亡率的风险。
在横断面分析中,与甲状腺功能正常的糖尿病患者相比,亚临床甲状腺功能减退与糖尿病肾病的患病率更高相关(优势比,3.15 [95%可信区间,1.48 - 6.69]),且未显示糖尿病视网膜病变的高患病率(优势比,1.15 [95%可信区间,0.59 - 2.26])。在44.0±7.4个月的随访期间,51名参与者发生心血管事件。在调整年龄、性别、糖化血红蛋白、其他标准心血管危险因素和药物后,亚临床甲状腺功能减退的2型糖尿病患者心血管事件风险显著增加(风险比,2.93;95%可信区间,1.15 - 7.48;P = 0.024),但在进一步调整尿白蛋白与肌酐比值后变得不显著(风险比,2.06;95%可信区间,0.67 - 6.36;P = 0.211)。心血管相关死亡率和总死亡率在不同甲状腺状态下无显著差异。
亚临床甲状腺功能减退的2型糖尿病患者与肾病和心血管事件风险增加相关,但与视网膜病变无关。我们的数据表明,2型糖尿病合并亚临床甲状腺功能减退时较高的心血管事件可能由肾病介导。